Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT02171832 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Liver Diseases

Interventions

DRUG: BI 1744 CL, low dose
DRUG: BI 1744 CL, high dose

Sponsor

Boehringer Ingelheim